

Data Sharing Statement

Zhou. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. *JAMA Oncol.* Published October 14, 2021. doi:10.1001/jamaoncol.2021.4761

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: Dr. Zhou reports that the data sets, including the redacted study protocol, redacted statistical analysis plan, and individual participant data supporting the results of the completed study, will be made available after the publication of the final study results within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.

How to access data: Please see the statement above.

When available: beginning date: 12-21-2021

Supporting Documents

Document types: None

Additional Information

Who can access the data: Researchers who provide a methodologically sound proposal.

Types of analyses: To be discussed with the lead study investigators.

Mechanisms of data availability: To be discussed with the lead study investigators.